CO2018014217A2 - Composiciones farmacéuticas que comprenden safinamida - Google Patents

Composiciones farmacéuticas que comprenden safinamida

Info

Publication number
CO2018014217A2
CO2018014217A2 CONC2018/0014217A CO2018014217A CO2018014217A2 CO 2018014217 A2 CO2018014217 A2 CO 2018014217A2 CO 2018014217 A CO2018014217 A CO 2018014217A CO 2018014217 A2 CO2018014217 A2 CO 2018014217A2
Authority
CO
Colombia
Prior art keywords
safinamide
pharmaceutical compositions
particles
preparing
pharmaceutically acceptable
Prior art date
Application number
CONC2018/0014217A
Other languages
English (en)
Inventor
Alberto Moretto
Lazzari Alessandra De
Deborah Teoli
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57113560&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018014217(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of CO2018014217A2 publication Critical patent/CO2018014217A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden safinamida y, más particularmente, a partículas enmascaradas del sabor que comprenden dicho ingrediente activo o sales farmacéuticamente aceptables de la misma, formas de dosificación oral que incluyen dichas partículas y un proceso para prepararlas.
CONC2018/0014217A 2016-05-31 2018-12-26 Composiciones farmacéuticas que comprenden safinamida CO2018014217A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUA2016A003981A ITUA20163981A1 (it) 2016-05-31 2016-05-31 Composizioni farmaceutiche comprendenti safinamide
PCT/EP2017/063063 WO2017207587A1 (en) 2016-05-31 2017-05-30 Pharmaceutical compositions comprising safinamide

Publications (1)

Publication Number Publication Date
CO2018014217A2 true CO2018014217A2 (es) 2019-03-18

Family

ID=57113560

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0014217A CO2018014217A2 (es) 2016-05-31 2018-12-26 Composiciones farmacéuticas que comprenden safinamida

Country Status (11)

Country Link
US (1) US10792257B2 (es)
JP (1) JP7146644B2 (es)
CN (1) CN109414404B (es)
AU (1) AU2017272621B2 (es)
BR (1) BR112018074434B1 (es)
CA (1) CA3025721C (es)
CO (1) CO2018014217A2 (es)
EA (1) EA201892842A1 (es)
IL (2) IL263247A (es)
IT (1) ITUA20163981A1 (es)
WO (1) WO2017207587A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018357886B2 (en) * 2017-11-02 2024-04-18 Zambon S.P.A. Pharmaceutical compositions comprising safinamide
ES2930376T3 (es) * 2017-12-08 2022-12-09 Hoffmann La Roche Formulación farmacéutica
WO2023041209A1 (en) * 2021-09-14 2023-03-23 Zach System Process for the preparation of safinamide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
KR101288286B1 (ko) 2005-08-10 2013-07-26 시오노기세이야쿠가부시키가이샤 쓴맛 감소제
WO2008119033A1 (en) * 2007-03-27 2008-10-02 Eurand, Inc. Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
KR101436516B1 (ko) * 2007-07-23 2014-09-02 주식회사태평양제약 코팅된 펠렛을 함유하는 현탁정 및 이의 제조방법
JP5777273B2 (ja) * 2008-07-10 2015-09-09 大正製薬株式会社 不快な呈味を有する薬物を含有する製剤粒子
WO2010010138A1 (en) 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
WO2011085188A1 (en) * 2010-01-07 2011-07-14 Eurand, Inc. Pharmaceutical compositions comprising anti-psychotic drugs
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
RS53612B1 (en) 2011-11-17 2015-04-30 Zambon S.P.A. SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING IBUPROFEN SALTS
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
JP6538321B2 (ja) 2014-09-19 2019-07-03 エスエス製薬株式会社 経口組成物
CN104546747A (zh) * 2014-11-20 2015-04-29 美吉斯制药（厦门）有限公司 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法
CN105456214A (zh) 2015-12-30 2016-04-06 蔡惠文 甲磺酸沙芬酰胺片

Also Published As

Publication number Publication date
BR112018074434A2 (pt) 2019-06-04
EA201892842A1 (ru) 2019-05-31
IL304109A (en) 2023-09-01
CA3025721C (en) 2024-03-26
IL263247A (en) 2019-01-31
JP2019520337A (ja) 2019-07-18
WO2017207587A1 (en) 2017-12-07
BR112018074434B1 (pt) 2024-02-20
US20200085769A1 (en) 2020-03-19
CN109414404B (zh) 2022-08-02
US10792257B2 (en) 2020-10-06
AU2017272621A1 (en) 2018-12-13
CN109414404A (zh) 2019-03-01
ITUA20163981A1 (it) 2017-12-01
CA3025721A1 (en) 2017-12-07
JP7146644B2 (ja) 2022-10-04
AU2017272621B2 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
ECSP17084331A (es) Formulaciones farmacéuticas
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
BR112017028140A2 (pt) formulações farmacêuticas
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PH12016501841A1 (en) Immunosuppressant formulation
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
PH12016502527B1 (en) Stabilized desmopressin
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina